Body mass index or microalbuminuria, which one is more important for the prediction and prevention of diastolic dysfunction in non diabetic hypertensive patients?

Numerous studies have now demonstrated that heart failure with a normal ejection fraction [HFnlEF] is common. Hypertension is also the most commonly associated cardiac condition in patients with HFnlEF. Despite the observed link between microalbuminuria, obesity, and cardiovascular disorders, this question has remained-Which is more important for the prediction and prevention of diastolic dysfunction in non diabetic hypertensive patients?' The current study was a cross section study conducted on a total of 126 non diabetic hypertensive patients screened to identify those with hypertension. Urine creatinine was measured by the picric acid method and urine albumin content was measured by a sensitive, nephelometric technique. The urinary albumin/creatinine ratio [UACR] was determined as an indicator of microalbuminuria. Complete two dimensional, doppler, and tissue doppler echocardiography was performed and the recording of the diastolic function parameters was carried out. High body mass index and high systolic blood pressure were positively correlated with the appearance of left ventricular hypertrophy, whereas, the UACR index had no significant relationship with hypertrophy. Multivariable analysis also showed that advanced age and systolic blood pressure were significantly associated with the E/E annulus parameter. According to our investigation obesity is more important than microalbuminuria for the prediction and prevention of diastolic dysfunction in non diabetic hypertensive patients

Anti-streptokinase antibody detection before and immediately after streptokinase therapy in patients with myocardial infarction

Myocardial infarction [MI] is one of the most common and serious diseases resulting from coronary artery occlusion and major reduction in blood flow. Streptokinase as a thrombolytic is considered the first and most important therapeutic intervention for reperfusion following MI in most countries including Iran. Our previous study showed that, the prevalence of high antibody titers against streptokinase was 13.5% in the studied population from Iran, which was 2.5 times more common than data from other studies. To evaluate anti-streptokinase antibody titers before and immediately after streptokinase administration and its relation to reperfusion therapy success rates. A total of 200 patients with acute MI was selected. Antibodies against streptokinase were measured before and 2 days after administration of streptokinase. Before streptokinase administration and every hour after streptokinase administration, for 3 consecutive hours, an ECG was taken from each participant and changes were evaluated in relation to antibody levels. Out of 200 patients, 42 [21%] had high levels of antibody titer. Out of these 42 patients, 13 [6.5%] still had measurable levels of anti-streptokinase antibody after streptokinase administration. Our results show the ability of the antistreptokinase antibody to neutralize the effects of streptokinase